ArticleScientific data2026
Malignant vs. Non-malignant Annotations on TCGA Breast Cancer Whole Slide Images for AI Analysis.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of malignant and non-malignant regions in breast cancer whole slide images (WSIs) is essential for understanding tumor heterogeneity and histopathological evaluation. Annotated data allows deep learning models to learn features and analyze histological structures. In this study, we obtained 50 breast cancer WSIs from The Cancer Genome Atlas (TCGA) and had an expert pathologist manually annotate malignant (n = 1,882) and non-malignant (n = 374) regions using QuPath. The annotated regions were independently reviewed by a second pathologist, achieving an inter-observer agreement of 99.95%. In addition, to assess annotations' quality, we trained a hybrid contrastive-supervised machine learning pipeline for patch-level malignant vs. non-malignant classification. The model achieved a high F1-score of 0.90 indicating that our annotations are comparable in quality to those presented in public datasets. The proposed dataset provides expert-quality annotations and a unique resource for benchmarking and developing AI models for breast cancer histopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.